Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sensipar

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

Novartis Gehry Building

Heart failure drug Entresto ‘could save 28,000 lives a year’

New independent report looks set to boost sales of Novartis’ drug into blockbuster territory

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

Amgen promotes Esteban Santos

He succeeds Madhavan Balachandran as executive vice president of operations

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links